Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial

ABSTRACT Background Lung cancer is a leading cause of cancer‐related deaths. Perioperative therapies, including neoadjuvant chemo‐immunotherapy, have improved outcomes, but combining them with antiangiogenic drugs may offer further benefits. This study evaluated the 3‐year efficacy and safety of neo...

Повний опис

Бібліографічні деталі

Автори:	Zhiyuan Gao, Yajie Mao, Yichen Sun, Liping Tong, Honggang Liu, Tianhu Wang, Changjian Shao, Hongtao Duan, Xiaolong Yan
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2025-08-01
Серія:	Thoracic Cancer
Предмети:	antiangiogensis follow‐up neoadjuvant NSCLC TD‐NeoFOUR
Онлайн доступ:	https://doi.org/10.1111/1759-7714.70149
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!